Medrx Co

Medrx Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Medrx Co (4586.T) as of Nov 3, 2026 is 409.90. In the previous year, Cash Conversion Cycle (CCC) was 94.42 — a change of 334.12% (higher).

Cash Conversion Cycle

409.90

YoY

334.12%

Last updated:

Cash Conversion Cycle (CCC) of Medrx Co is 2025 409.90 . Cash Conversion Cycle (CCC) of Medrx Co was 2024 94.42 . It decreases by 334.12% higher compared to the previous year.

The Medrx Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
365.21 JPY
Jan 1, 2019
-446.92 JPY
Jan 1, 2020
-421.30 JPY
Jan 1, 2021
-402.66 JPY
Jan 1, 2022
62.10 JPY
Jan 1, 2023
76.10 JPY
Jan 1, 2024
94.42 JPY
Jan 1, 2025
409.90 JPY
The Medrx Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
409.90+334.12%
94.42+24.08%
76.10+22.54%
62.10-115.42%
-402.66-4.43%
-421.30-5.73%
-446.92-222.38%
365.21+7.56%
339.55+44.86%
234.40+89.69%
123.57+0.50%
122.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Cash Conversion Cycle (CCC) of Medrx Co is 409.90 in 2025.

Cash Conversion Cycle (CCC) of Medrx Co changed from 94.42 to 409.90, representing a 334.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co